Overview
Corporate Profile
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>
Stock Chart
Stock Quote
| (Common Stock) | |
| Exchange | (US Dollar) |
| Price | |
| Change (%) | |
| Intraday High | |
| Intraday Low | |
| Volume | |
|
|
|
Copyright Nasdaq. Minimum 15 minutes delayed.
RECENT NEWS
More >>| Date | Title | ||||
|---|---|---|---|---|---|
|
06/11/18
|
Summary ToggleClovis Oncology to Present at the Goldman Sachs 39th Annual Global Healthcare Conference 2018 |
BOULDER, Colo. --(BUSINESS WIRE)--Jun. 11, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 4:00 PM Pacific Time . |
 |
||
|
06/04/18
|
Summary ToggleClovis Oncology Submits Application to EMA to Expand Use of Rubraca®▼ (rucaparib) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer | Untitled Document Submission based on positive phase 3 ARIEL3 clinical trial in which rucaparib significantly improved PFS in all primary efficacy ovarian cancer patient populations studied Timing of maintenance treatment application submission to EMA may allow for a CHMP opinion by year-end 2018 |
|
||
|
06/03/18
|
Summary ToggleClovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers | Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca® (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer BOULDER, Colo. and MORRIS PLAINS, N.J. , June 03, 2018 (GLOBE NEWSWIRE) -- Clovis Oncology, |
|